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Purpose: Large inter-patient variability in patient response to the chemotherapeutic 
agent, 5-Fluorouracil (5FU), makes markers for predicting 5FU response highly 
desirable. We describe here a pathway-based gene expression analysis of the relative 
roles of all known components of 5FU transport, metabolism, its downstream effects and 
co-factor (folate) metabolism in determining 5FU sensitivity in cell lines, xenografts and 
tumours. Experimental design: The expression of 96 rationally-selected genes was measured by 
low-density array real-time PCR in 21 colorectal cancer cell lines, 14 xenografts and 25 
tumors. Samples were grouped by unsupervised hierarchical clustering and the groups 
tested for associations with respective sensitivity, response and patient survival data. 
Patterns of expression changes of the 96 genes in 5FU sensitive and resistant cells 
following a time course of 5FU treatment were also clustered to identify the most 
defining expression changes, and their component genes. siRNA knockdown was 
performed to verify the influence of the top candidate on 5FU sensitivity in-vitro.  
Results:  5FU sensitivity associated with clustered groups for xenografts and tumours, 
but not cell lines. CTPS2 and NME4 were the genes common to the significantly 
differentially regulated genes in xenografts and tumors. CTPS2 was also in the group of 
genes with the most distinct expression change following 5FU treatment in sensitive and 
resistant cell lines. siRNA knockdown of CTPS2 reduced sensitivity to 5FU.  
Conclusion: Pathway-based analysis in multiple cancer models identifies CTPS2 
expression as a major determinant of 5FU sensitivity. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Colorectal Cancer 
Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide 
(Greenlee et al., 2000). In Singapore, CRC is the most prevalent cancer in both men and 
women combined and the incidence is increasing very rapidly with about 1000 new cases 
diagnosed annually (Singapore Cancer Registry Report No. 6). The probability of 
developing CRC increases with age, with 1 in 124 males and 1 in 149 females aged 
between 40 to 59 years old developing CRC, increases to 1 in 29 males and 1 in 33 
females for age between 60 to 79 (Greenlee et al., 2000).  
 
Surgical resection remains the primary treatment for patients with CRC. Resected 
samples are then sent for pathological evaluation which provides prognostic information 
based on tumor staging and facilitates treatment decision. Chemotherapy and/or 
radiotherapy is often given in adjuvant settings, and less commonly as neoadjuvant 
treatment. For patients whose surgery is deemed non-curative, for example, in metastatic 
colorectal cancer, chemotherapy or radiotherapy may be used as primary treatment 
(palliative). In colon cancer, whereby recurrence to distant sites like liver, bone and lungs 
is not uncommon, systemic chemotherapy given in adjuvant settings is more preferred to 
radiotherapy (Midgley et al., 1999). In contrast, about 50% of recurrences of rectal 
cancer localize in the pelvic region and hence, local radiotherapy is a preferred treatment 




Forty to 60% of the CRC patient population is diagnosed with stage II or stage III disease 
(Aranha et al., 2007). After curative surgery, stage III patients experience 50-60% chance 
of developing disease recurrence. Published clinical trials have proved the beneficial 
effects of adjuvant chemotherapy in improving curative rates in resected stage III cancer 
(Wolmark et al., 1993; Moertel et al., 1995; Bleiberg et al., 2000). As such, the use of 
adjuvant chemotherapy for stage III cancer has since become the standard care. In 
contrast, patients with stage II colorectal cancer, the use of adjuvant therapy remains 
controversial and is not routinely recommended (Benson et al., 2004). However, the 
recurrence rate for stage II patients is about 20%, which is considerably high. This poses 
a dilemma for clinicians in deciding the appropriateness of adjuvant chemotherapy in 
stage II disease, so not to expose patients to unnecessary side effects while ensuring 
clinical benefits.   
 
1.2 5-fluorouracil 
In 1957, fluoropyrimidines were rationally designed based on the observation that rat 
hepatomas utilize radiolabelled uracil more rapidly than normal tissues, indicating that 
uracil metabolism was a potential target for chemotherapy (Heidelberger et al., 1957). 5-
fluorouracil (5FU), then synthesized with the presence of a fluorine atom on the fifth 
carbon of naturally occurring uracil is readily taken up and metabolized by cells, thus 
interfering with uracil metabolism (Figure 1). The more rapid uracil metabolism in tumor 
cells provides 5FU the advantage of being tumor selective as the rate of 5FU uptake goes 
hand-in-hand with uracil. With well demonstrated cytotoxicity, 5FU has since been 
widely used in the treatment of a number of cancer types, including colorectal, breast, 
LITERATURE REVIEW 
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head and neck cancer (Longley et al., 2003). Though being tumor selective, 5FU also 
causes normal tissues toxicities like nausea, vomiting, diarrhea, myelosuppression, 
mucositis, hand-foot disease, and, more rarely cardiac and neurotoxicities (Grem et al., 
2000). 
 
Figure 1: Chemical structure of uracil and 5-fluorouracil (5FU). The hydrogen atom at 




1.2.1 Transport  
As a synthetic nucleoside, uptake of 5FU into cells has been shown to occur via the same 
non-concentrative, saturable mechanism as uracil (Wohlhueter et al., 1980), via an active, 
concentrative mechanism (Yamamoto et al., 1981), or via nonfacilitated diffusion (Kessel 
et al., 1967). It was later reported that 5FU enters human erythrocytes via same carriers 
that transport purine nucleobases and nonfacilitated diffusion (Domin et al., 1993).  
 
It is now recognized that uptake transporters responsible for translocation of nucleoside 
and nucleobases are members of the equilibrative nucleoside transporters (ENT, 
SLC29A) family and concentrative nucleoside transporter (CNT, SLC28A) family 
(Pastor-Aglada et al., 1998). The ENTs (comprises 4 isoforms, ENT1-4) transport 
hydrophilic nucleosides and nucleoside analogs by bi-directional facilitated diffusion 
(Baldwin et al., 2004). They accept both purine and pyrimidine nucleosides but differ in 
their sensitivity to inhibition by nitrobenzylthioinosine (NBMPR). Human ENT1 
(hENT1, an equilibrative sensitive, es-type transporter) is inhibited by nanomolar 
concentration of NBMPR, whereas hENT2 (an equilibrative insensitive, ei-type 
transporter) is unaffected by low concentrations of NBPMR. Besides purine and 
pyrimidine analogs, ei-type transporter also transports nucleobases (Ritzel et al., 2001). 
 
On the other hand, CNT transporters are Na+-dependent and show different substrate 
specificity and pharmacological properties (Pastor-Aglada et al., 1998). A number of 
isoforms (CNT1-3) are known to exist: hCNT1 (a concentrative NBMPR-insensitive 
thymidine selective or cit-type transporter) is pyrimidine-preferring; hCNT2 (a 
LITERATURE REVIEW 
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concentrative insensitive and formycin B-selective or cif-type transporter) is purine-
preferring; hCNT3 (a concentrative NBMPR-insensitive or cib-type tranporter) is broadly 
selective, transporting both purine and pyrimidine nucleosides and also nucleobases 
(Pastor-Aglada et al., 1998, Ritzel et al., 2001). In another study investigating the role of 
hCNT1 in cytotoxicity of 5’-deoxy-5-fluorouridine (5’-DFUR), a 5FU prodrug, it was 
found that 5’-DFUR is an hCNT1 substrate, but 5FU is not (Mata et al., 2001).  Efflux 
transporters for 5FU cytotoxic intracellular metabolite has first been identified by Guo et 
al. in an in-vitro transport assay (Guo et al., 2003).  Like drug uptake mechanism, efflux 
transport could have important implication in chemotherapeutic cytotoxicity as efflux 
mechanism also determines drug availability in tissues. 
 
1.2.2 Metabolism 
Biotransformation of 5FU is important for its clinical effectiveness. The balance between 
anabolism and catabolism determines the availability of 5FU in tissues (Heggie et al., 
1987). As a uracil analogue, 5FU undergoes the de novo anabolic and catabolic pathways 
used by uracil. The anabolism of 5FU to nucleotides occurs through several pathways 
(Figure 2 and 3): 
(1)  a reversible conversion of 5FU to 5-fluoro-2’-deoxyuridine (FdUrd) by thymidine 
phosphorylase (TP), followed by phosphorylation to 5-fluoro-2’-deoxyuridine-5’-




(2) a transformation of 5FU to 5-fluorouridine (FUrd) by uridine phosphorylase (UP), 
followed by phosphorylation to 5-fluorouridine monophosphate (FUMP) by uridine 
kinase (UK) (Skold, 1958); 
(3) a direct conversion of 5FU to FUMP by orotate phosphoribosyltransferase 
(OPRT) which directly transfers a ribose phosphate from phosphoribosyl pyrophosphate 
(PRPP) to 5FU (Reyes et al., 1969).  
 
Another pathway for FdUMP formation is via dephosphorylation of fluorodeoxyuridine-
5’-diphosphate (FdUDP), which is converted from fluoridine-5-diphosphate (FUDP) by 
ribonucleotide reductase.  FdUMP and FdUDP are substrates for thymidine kinases, 
resulting in the formation of fluorodeoxyuridine-5’-triphosphate (FdUTP). FUMP formed 
from pathways described in (2) and (3) is sequentially phosphorylated to FUDP and 
fluorouridine-5’-triphosphate (FUTP). 
 
Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme of 5FU 
degradation, catabolising approximately 80% of 5FU to dihydrofluorouracil (DHFU) 
(Diasio and Harris, 1989).  Dihydropyrimidinase (DHP) subsequently converts DHFU to 
5-fluoroureido-propionic acid (FUPA), followed by conversion to fluoro-β-alanine 




Figure 2: 5-fluorouracil (5FU) metabolism. 5FU is converted to three main active 
metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). 5FU is directly converted 
to FUMP by orotate phosphoribosyltransferase (OPRT) phosphoribosyl pyrophosphate 
(PRPP) as the co-factor, or indirectly by fluorouridine (FUR), acting through uridine 
phosphorylase (UP) followed by uridine kinase (UK). FUMP is sequentially 
phosphorylated to fluorouridine diphosphate (FUDP) and fluorodeoxyuridine-5’-
diphosphate (FdUDP), which can either be phosphorylated or dephosphorylated to 
FdUTP and FdUMP, respectively. Alternatively, 5FU is converted via thymidine 
phosphorylase (TP) to flurodeoxyuridine (FUDR), which is then phosphorylated by 
thymidine kinase (TK) to FdUMP. Dihydropyrimidine dehydrogenase (DPD) catabolizes 






Figure 3: Pathways of fluoropyrimdine and folate metabolism and downstream events.  
The anti-tumor activity of 5FU is via inhibition of thymidylate synthase (TS), 
incorporation into RNA and DNA. The prominent candidate fluoropyrimidine predictive 
indicators are highlighted in large font and bold (Adapted from Soong and Diasio, 2005). 
3UP: 3-ureidoproionoic acid; 3UP: 3-ureidopropionase; 5FU: 5-fluorouracil; BAL: b alanine; CDA: 
Cytidine deaminase; CE: Carboxylesterase; CK: Cytidylate kinase; CYP450: Cytochrome P450; DHF: 
Dihydrofolate; DHFR: Dihydrofolate reductase; DHP: Dihydropyrimidinase; DHU: Dihydrouracil; DNA: 
Deoxyribonucleic acid; DNAPol: DNA polymerase; DNMT: DNA methyltransferase; DPD: 
Dihydropyrimidine dehydrogenase; dUDP: Deoxyuridine diphosphate; dUMP: Deoxyuridine 
monophosphate;  dUrd: Deoxyuridine; dUTP: Deoxyuridine triphosphate; dUTPPP: Deoxy-UTP-
pyrophosphatase; F: fluoro; MS: Methionine synthase; NDK: Nucleotide diphosphate kinase; NDPase: 
Nucleoside dihposphatase; NMK: Nucleotide monophosphate kinase; NSase: Nucleosidase; NTase: 5’-
nucleotidase; OPRT: Orotate phosphoribosyltransferase; RDR: Ribonucleotide diphosphate reductase; 
RNA Ribonucleic acid; RNAPol: RNA polymerase; SAH: S-adenosylhomocysteine; SAM: S-
adenosylmethionine; THF: Tetrahydrofolate; TK: Thymidine kinase; TP: Thymidine phosphorylase; TS: 
Thymidylate synthase; UDP: Uridine diphosphate; UKL Uridine kinase; UMP: Uridine monophosphate; 
UNSases: Uridine nucleosidase; UP: Uridine phosphorylase; Urd: Uridine; UTP: Uridine triphosphate.  
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1.2.3 Mechanism of Action 
The antitumor activity of 5FU is exerted by its metabolites, mainly FdUMP, FdUTP and 
FUTP. At least three mechanisms of action have been identified for 5FU toxicity: 
inhibition of thymidylate synthase (TS), incorporation into RNA and also DNA (Figure 
3). 
 
FdUMP inhibits TS enzyme through the formation of a stable ternary complex with 5,10-
methylene-tetrahydrofolate (CH2THF), thereby blocking the binding of natural substrate 
dUMP (Sommer et al., 1974). The failure of dUMP binding prevents deoxythymidine 
monophosphate (dTMP) synthesis, which is important for deoxythymidine triphosphate 
(dTTP) synthesis. Disruption of dTTP synthesis leads to deoxynucleotide pool 
imbalances, thus interrupting DNA synthesis.  
 
CH2THF, the reduced-folate cofactor essential for the tight binding of FdUMP to TS is 
derived from folic acid in diet. Figure 3 (Soong et al., 2005) summarizes the key enzymes 
involved in folate metabolism and illustrates the role of CH2THF in TS inhibition. Folate 
deficiency has been shown to incur resistance to 5FU therapy (Branda et al., 1998).  
 
Besides disrupting the dTMP and dTTP pools, TS inhibition also leads to accumulation 
of dUMP which in turn results in increased levels of dUTP. Together with FdUTP, dUTP 
can be misincorporated into DNA by DNA polymerase (Longley et al., 2003). There are 
two enzymes which prevent the misincoporation of FdUTP and dUTP into DNA: (1) 
dUTP pyrophosphatase (dUTPase) which hydrolyses FdUTP to FdUMP and; (2) uracil-
LITERATURE REVIEW 
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DNA-glycosylase, a DNA repair enzyme which hydrolyses the fluorouracil-deoxyribose 
glycosyl bond of (F)dUMP on DNA, thereby leaving an apyrimidinic site in DNA 
(Mauro et al., 1993). The lesion in DNA is recognized by an apurinic/apyrimidinic 
endonuclease, then resulting in single strand break, which is subsequently repaired. The 
efficiency of DNA repair mechanism is further weakened by the depletion of dTTP. 
Furthermore, 5FU substituted DNA is a weaker substrate for uracil-DNA-glycosylase as 
compared to uracil.  
 
The incorporation of FUTP into RNA by the action of RNA polymerase also contributes 
to 5FU cytotoxicity. Various effects that occur as a result of 5FU-RNA incorporation 
include decrease in net RNA synthesis, disruption of normal RNA processing and 
function, inhibition of mRNA polyadenylation and alteration of secondary structure of 
RNA (Longley et al., 2003).  
 
1.3 Fluorouracil-based therapies 
For the past few decades, 5FU has been administered intravenously in various forms of 
different schedules, and in both adjuvant and palliative settings. Firstly used as a single 
agent, 5FU has an overall response rate (RR) of 10-15% (Advanced Colorectal Cancer 
Meta-Analysis Project, 1992; Thirion et al., 2004). In view of the poor clinical outcome, 
many strategies have been developed to improve survival benefits and overcome drug 
resistance. Few of the early biochemical modulators used to increase 5FU cytotoxicity 
includes leucovorin (LV), levamisole, methotrexate (MTX) and interferon. Levamisole 
has been found to be effective in treating colon cancer when combined with 5FU 
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(Moertel et al., 1990). However, the long term clinical outcome of this combination 
remains unclear (Cassidy 1994; Chlebowski et al., 1994). The use of MTX and interferon 
has not been translated into clinical practice today as the results from randomized trials 
failed to support their clinical benefit (Thirion et al., 2001; Punt et al., 2002). LV, a 
folinic acid, helps to increase the intracellular reduced folate pools, thus increasing the 
stability of folate-FdUMP-TS ternary complex. The maintenance of a stable ternary 
complex is essential for 5FU cytotoxicity. A meta-analysis of 9 randomized clinical trials 
demonstrated a response rate in favor of 5FU/ LV over 5FU alone (23% vs 11%) but did 
not improve overall survival (OS) (Advanced Colorectal Cancer Meta-Analysis Project, 
1992).  
  
As rapid degradation by DPD greatly affects 5FU bioavailability, the oral Uracil/Ftorafur 
(UFT) formulation have been developed to reduce 5FU degradation by saturating DPD 
activity with uracil. It has been shown that UFT/LV offered similar response rates as 
5FU/LV with fewer side effects (Douillard et al., 2002). In the late 1990s, capecitabine, a 
5FU oral prodrug, was designed to by-pass DPD degradation in the liver. It has been 
shown that capecitabine produced higher response rate than 5FU/LV (25% vs 16%), but 
time to disease progression and survival were not significantly different for both 
treatment groups (Hoff et al., 2001). Fewer side effects were observed in patients treated 
with capecitabine, except hand-foot syndrome which develops in 25% of these patients 




Novel combinations of 5FU and its analogs with agents that have different mechanisms 
of actions like irinotecan and oxaliplatin further improves clinical outcome in colorectal 
cancer. The MOSAIC trial showed that stage II or III colon cancer patients treated with 
5FU, LV and oxaliplatin (FOLFOX) achieved better disease-free survival at 3 years as 
compared to infusional 5FU/LV therapy (78.2% vs 72.9%), although no difference was 
noted for OS (Andre et al., 2004). Randomized trials have shown that irinotecan given in 
combination with 5FU/LV (FOLFIRI) to be superior to 5FU/LV regimen (Saltz et al., 
2000; Douillard et al., 2000). Saltz and colleagues reported that metastatic colorectal 
cancer patients treated with irinotecan, 5FU and LV had a significantly higher RR, longer 
progression-free survival (PFS) and longer OS than those treated with 5FU and LV alone 
(Saltz et al., 2000). Similar observations were also reported by Douillard et al. (2000). 
 
Other newer FDA-approved chemotherapeutic agents including monoclonal antibodies 
like bevacizmab and cetuximab have been used in combination for the treatment of 
metastatic colorectal cancer. Bevacizumab, targeting the vascular endothelial growth 
factor, was the first targeted drug to show clinical benefit in metastatic CRC (Fakih 
In a combined analysis of 3 randomized studies, metastatic colorectal cancer patients 
treated with 5FU/LV/bevacizumab had improved RR, longer PFS and OS (Fairooz 2005) 
compared to 5FU/LV alone. Cetuximab, which targets the epidermal growth factor 
receptor provide good clinical efficacy when used in combinations with 5-fluorouracil 
and/or irinotecan (Reynolds et al., 2004). In the CRYSTAL phase III trial, patients who 
received FOLFIRI and cetuximab had a significantly longer progression-free survival and 




1. 4 Molecular determinants of 5FU sensitivity 
1. 4.1 Candidate gene approach 
The ability to predict 5FU response from its metabolism and cytotoxic mechanisms was 
first demonstrated using candidate gene approaches. Early studies have associated 
resistance to 5FU with the loss in activity of uridine kinase (Reichard et al., 1962), 
uridine phosphorylase (Goldberg et al., 1966) and pyrimidine phosphoribosyltransferase 
(Kasbekar et al., 1963), leading to changes in 5FU metabolite levels. Soon after TS 
inhibition by 5-FdUMP was identified as an important determinant for 5FU cytotoxicity, 
leading the degree of TS inhibition and TS levels to be deemed as potential indicators for 
response. Many studies have demonstrated the relationship between elevated TS 
expression/activity and 5FU resistance (Berger et al., 1985; Clark et al., 1987; Johnston 
et al., 1992; Johnston et al., 1995).  The general consensus associated low TS 
expression/activity with improved response to 5FU (Johnston et al., 1995; Leichman et 
al., 1995; Bathe et al., 1999; Wong et al., 2001; Fernandez-Contreras et al., 2006). 
However, some reports have shown no relationship between these parameters (Findlay et 
al., 1997; Allegra et al., 2003; Johnston et al., 2003) or reverse association, i.e. high TS 
expression provides disease-free survival benefit (Berglund et al., 2002; Edler et al., 
2002). Polymorphism studies have revealed the presence of variable number tandemly 
repeated polymorphic regulatory sequences (VNTR) in the TS enhancer region (TSER) 
correlates with TS expression, with triple repeat (3R) having higher TS expression than 
double repeat (2R) (Horie et al., 1995; Pullarkat et al., 2001). Clinical studies later 
showed that homozygous 3R/3R patients had a lower clinical response as compared to 
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others (Pullarkat et al., 2001; Etienne et al., 2002), or did not obtain a survival benefit 
from 5FU (Iacopetta et al., 2001). In the second repeat within the VNTR, the presence of 
a functional G>C single nucleotide polymorphism (SNP) at bp 58 was associated with 
reduced TS expression (Kawakami et al., 2003). Another TS polymorphism consisting of 
a 6 bp deletion at bp 1494 in the 3’-untraslated region is associated with reduced TS 
expression in colorectal tumors (Ulrich et al., 2000).  
 
The catabolic enzyme, DPD, is another important determinant for responsiveness to 5FU 
since its level and activity greatly affects 5FU availability. DPD activity is inversely 
associated with 5FU sensitivity: 5FU resistance being observed in patients having high 
DPD level/activity (Ishikawa et al., 1999) whilst patients with DPD deficiency suffering 
from severe toxicities (Tuchman et al., 1985; Milano et al., 1999). DPD deficiency has 
been linked with a DPD exon 14 deletion variant and thus identified as a potential 
indicator of 5FU response (Meinsma et al., 1995). Nevertheless, there are few studies 
which failed to observe such inverse relationship between DPD expression/activity and 
5FU response (Jakob et al., 2005; Kinoshita et al., 2007; Yamada et al., 2008). 
 
Other genes or proteins involved in the metabolic pathway identified as molecular 
markers for 5FU response includes TP, OPRT and TK. The role of TP in determining 
5FU sensitivity is unclear. Metzger et al. reported that high TP level in colorectal tumors 
is associated with nonresponse to 5FU (Metzger et al., 1999) but opposite findings have 
also been reported (Schwartz et al., 1995; Yasuno et al., 2005).  Colorectal cancer 
patients with high OPRT activity were reported to have better 5FU efficacy (Sakamoto et 
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al., 2007) and better disease-free and overall survival when treated with 5FU based 
chemotherapy (Ochiai et al., 2006). However, no relationship between OPRT level and 
5FU efficacy was observed by Ishida et al. (2005). Decreased TK activity has been 
shown to be associated with 5FU insensitivity (van der Wilt et al., 1998).  
 
As CH2THF is crucial in maintaining a stable ternary complex with TS and 5-FdUMP, 
folate metabolism becomes the focus for 5FU response prediction. Intracellular CH2THF 
concentration is mainly controlled by MTHFR. Several polymorphisms are commonly 
found in the MTHFR gene, with 677C>T polymorphism in exon 4 and 1298A>C 
polymorphism in exon 7 being most commonly linked with altered TS activity (Etienne 
et al., 2007). The 677C>T polymorphism is frequently associated with enhanced 5FU 
activity due to increased CH2THF levels (Cohen et al., 2003; Etienne et al., 2004). 
Higher 5FU sensitivity was observed in mutated A1298C variants of MTHFR (Etienne et 
al., 2004). 
 
A promising molecular marker related to the downstream mechanisms of 5FU is p53. 
Loss of p53 function may contribute to 5FU resistance as p53-deficient cells fail to 
undergo p53-mediated apoptosis (Longley et al., 2002).  Mutations in p53 occur in more 
than 50% of colorectal tumors, often resulting in p53 overexpression (Brett et al., 1996). 
Tumor overexpression of p53 was associated with lower response rate and higher rate of 
deterioration radiologically and clinically. Others have also provided evidence for the 
correlation between mutations/deletions of p53 with 5FU resistance (Lowe et al., 1993; 




Some studies have investigated these determinants in minimal combinations, as 












Table 1: Overview of studies on gene/protein expression levels in relation to 5FU 
chemosensitivity. 
 
Gene/protein Sample Outcome References 
RNA    
UP, TP 8 colorectal 
cancer cell 
lines 
UP and TP expression were 
predictive for 5FU cytotoxicity in 
5/7 cell lines 
Mader et al., 
1997 
DPD, TP, TS 33 colorectal 
tumors 
Colorectal tumors responding to 
5FU had low DPD, TS and TP 
Salonga et al., 
2000 
DPD, TS 5 xenografts, 
85 gastric 
tumors 
Low TS and DPD was associated 
with 5FU sensitivity 
Fujiwara et al., 
2002 
DPD, TS 37 colorectal 
tumors 
Patients with low TS and DPD had 
better response rate and longer 
median survival time 






UFT-responding tumors had a 
statistically higher OPRT/DPD 
ratio survived longer than those 
with low ratio 
Ichikawa et al., 
2003 
DPD, TS 23 colorectal 
tumors 
Increase in TS in 5FU-sensitive 
colorectal cancers 
Inoue et al., 
2005 
DPD, TP, TS 4 colorectal 
cancer cell 
lines 
Higher sensitivity to 5FU of cell 
lines with the lowest TS 
expression 
Amatori et al., 
2006 
DPD, OPRT, 
TP, TS, UP 
HCT116 
xenotransplant 
DPD and TP levels were  inversely 
correlated with 5FU sensitivity 






DPD levels and OPRT/DPD ratio 
is weakly correlated with 5FU 
sensitivity 






Patients with high OPRT had 
longer disease-free and overall 
survival 
Yamada et al., 
2008 
    




5FU resistance was due to reduced 
activities of 5FU anabolizing 
enzymes  
Inaba et al., 
1996 
DPD, TP, TS 41 colon 
tumors 
Intratumoral TS protein expression 
was inversely correlated with 
response to chemotherapy 
Cascinu et al., 
1999 
DPD, TP, TS 40 rectal 
tumors 
High TS and low TP was 
associated with nonresponse to 
5FU 





DPD, TP, TS 62 colorectal 
tumors 
Patients with low TS and DPD had 




DPD, TP, TS 967 colorectal 
tumors 
Low TS and DPD were prognostic 
for worse outcome in patients 
treated by surgery alone; low 
DPD, TP and TS were prognostics 
for better outcome in patients 
treated with 5FU 
Soong et al., 
2008 
p53, TS 122 colorectal 
tumors 
No relationship between TS and 
p53 expression with 5FU response 
Berglund et al., 
2002 
p53, TS 706 colorectal 
tumors 
None of the markers could be used 
to predict benefit from 5FU 
treatment 
Allegra et al., 
2003 
p53, TS 967 colorectal 
cancer 
None of the markers was 
significantly associated with 
survival 
Popat et al., 
2006 
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1.4.2 Genome-wide approach  
As 5FU metabolism is a complex event and its biochemical action involves multiple 
targets, multiple genes involved in pyrimidine metabolism and activity may be associated 
with 5FU sensitivity. Approximately 50 genes identified from Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway database are found to be involved in the normal 
pyrimidine metabolism which is important for thymidine and cytidine synthesis 
(http://www.genome.ad.jp/kegg/pathway.html). Insufficient folate supply due to impaired 
folate metabolism may also affect 5FU action as MTHF is crucial for stabilizing the 
tertiary complex formed with 5FU and thymidylate synthase. Also, there is growing body 
of evidence which suggests the involvement of many other genes/proteins in the transport 
mechanism, stress response and DNA repair in influencing 5FU sensitivity.  
 
The role of efflux transporters in determining FP response has been investigated by Guo 
and coworkers in an in-vitro transport assay (Guo et al., 2003). Using MRP8-transfected 
LLC-PK1 cells, the investigators demonstrated that MRP8 (ABCC11) functions as a 
resistance factor for 5FU by mediating the efflux of 5-FdUMP, the intracellular cytotoxic 
metabolite of 5FU. The role of MRP8 in 5FU resistance is also confirmed by Oguri and 
colleagues (Oguri et al., 2007). The high degree of structural resemblance between 
MRP8 and MRP9 (Tammur et al., 2001, Yabuuchi et al., 2001) suggests that MRP9 may 
participate in 5FU efflux. MRP5-transfected cells were found to be resistant to 5FU (Pratt 
et al., 2005). However, a review by Borst and coworkers on MRP4 and MRP5 found no 
evidence that the transport of nucleotide analogs results in resistance in vivo (Borst et al., 
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2007). Further investigation on the role of 5FU transport in clinical resistance to 5FU is 
clearly needed. 
 
Overexpression of DNA repair genes gives rise to tumor resistance to DNA-damaging 
agents (Yu et al., 2006). Deficiency in DNA mismatch repair (MMR) genes MLH1, 
MSH2, MSH6 and PMS2 was shown to have a negative impact on overall survival in 
CRC, suggesting that MMR status may contribute to decision making regarding treatment 
approaches (Gologan et al., 2005). Ide et al. has reported an association between low 
MLH1 expression with better disease-free survival rate in 94 colorectal cancer patients 
(Ide et al., 2008). Cell lines deficient of Smug-1, a DNA glycosylase in base excision 
repair mechanism, were found to be highly sensitive to 5FU cytotoxicity. Figure 4 shows 
the genes involved in the DNA repair mechanisms and stress response in relation to 5FU 





Figure 4: Activation of DNA repair mechanisms and stress response in relation to 5FU 
effects. 5FU-induced DNA damage leads to activation of ataxia telangiectasia mutated 
(ATM) and ataxia telangiectasia related (ATR). ATM phosphorylates Chk2 while ATR 
phosphorylates Chk1. Both Chk2 and Chk1 phosphorylates p53, leading to cell cycle 
arrest, apoptosis and enhanced DNA repair. Poly(ADP-ribose) polymerase (PARP)-1 and 
PARP-2 proteins are also play an important role in DNA repair.  
 
DNA repair 
UNG, SMUG1, XRCC1, 
HMGB1, MLH1, MSH2, 
MSH6, PMS2, Exo1 
 
DNA damage PARP1 & 2 
ATR/ATM 
CHK1 









With the advent of microarray technology, gene expression profiling has been applied to 
identifying determinants of 5FU response at a genome/proteome-wide level (Table 2). 
Several model systems have been investigated for 5FU-based therapies in the treatment 
of colorectal cancer, including the cancer cell lines, tumor xenografts and primary 
as reviewed by Mariadason et al. (Mariadason et al., 2004). These studies analyzed basal 
gene expression profiles and identified determinants for pre-treatment drug response. 
Genome-wide expression analysis has also been applied to identifying determinants from 
after-drug treatment by identifying genes that were altered following drug exposure (De 
Angelis et al., 2006; Boyer et al., 2006). 
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Table 2: Summary of genome-wide and proteomic studies to identify determinants for 
5FU-based chemosensitivities. 
 
Sample Compounds Outcome References 









Negative correlation between DPYD 
expression and 5FU potency 







Survivin was highly expressed in 5FU 
resistant cells while members of the 
aldo-keto reductase and aldehyde 
dehydrogenase families and galectin 4 
were highly expressed in 5FU 
responsive cells 





5FU 20 genes of the highest correlation to 









Expression of 50 genes not previously 
reported were correlated with 5FU-
induced-apoptosis and significantly 
predicted response to 5FU 
Mariadason 






Expression levels of 54 genes not 
previously reported were significantly 







5FU Low SPARC expression in resistant 
cell line 







5FU 81 genes were identified to be related 








Expression levels of TNFRSF1B, 
SLC35F5 and OPRT were significantly 
different in 5FU responders and non-
responders 
Matsuyama 






Tumors with low DPYD expression 
had high sensitivity to 5FU based 
therapy, except S-1 
Ooyama et 
al., 2006 
    
Protein    
Colon cancer 
cell lines 
5FU Metabotropic glutamate receptor 4 was 
overexpressed in 5FU resistant cells 







5FU Lower expression of the alpha subunit 
of mitochondrial F(1)F(0)-ATP 
synthase in 5FU-resistant cells 
Shin et al., 
2005 
SW480 cells  5FU After 5FU treatment, cyclophilin A, 
cytokeratin (CK) 19, CK8, ras-related 
nuclear protein, heat shock protein 
(hsp) 27 and peroxiredoxin 6 (Prx 6) 
were upregulated whereas hsp60, 
CK18, CK9, carbamoylphosphate 
synthetase I, alpha-enolase, hsp70, 
nm23 and beta-actin were down-
regulated 
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1.5 Study approaches 
In recognizing the value of identifying determinants for 5FU pre-treatment response 
prediction and the lack of promising markers for clinical implementation, a multiple-gene 
approach based on real-time quantitative RT-PCR was employed in this study, focusing 
on genes from fluoropyridimine- and closely related cellular pathways. This pathway 
based analysis of best characterized genes enables us to better investigate the combined 
effects of gene expression relevant to 5FU mechanism as well as limits the potential 
genes of interest and avoids too many irrelevant, false positive or negative markers. 
Furthermore, genome-wide analyses require a reasonably large sample size to accurately 
determine the predictive value of a gene and this requirement is often unmet. 
 
In order to identify factors robustly related to 5FU sensitivity, we have investigated cell 
lines, tumor xenografts and clinical samples. Cell lines and tumor xenografts allows 
assessment of tumor-directed effects, which is less achievable in humans. Furthermore, it 
was reported that antitumor effects in human tumor xenograft models correlate well with 
clinical effects (Tashiro et al., 1989). 
  
Examination on regulation patterns of 5FU pathway genes in response to 5FU timepoint 
treatment in resistant and sensitive cell lines was used as another approach to identifying 
potential determinants for 5FU sensitivity. RNAi technology was used to validate the 




1.5.1 Quantification of mRNA expression using real-time PCR  
Quantitative RT-PCR (Q-PCR) is sensible method for quantifying gene expression levels 
and could be realized with small amount of tissue. However, quantification of many 
genes laborious as primers and probes specific for each gene need to be individually 
designed. Although high-throughput gene expression profiling with microarray is a 
powerful alternative and allows more genes to be investigated, it requires more sample 
tissues and there is a higher probability of having false positive or negative markers that 
still require validation with Q-PCR.  
 
The introduction of low-density array (LDA) based on the principle of TaqMan Q-PCR 
has made the quantification of multiple genes easier and faster than before, requiring 
much less template cDNA than conventional Q-PCR. The chemistry employed in the 
real-time Q-PCR is to use a Taq polymerase that has a 5′exonuclease activity. The 
principle of the process was first described by Holland et al. (Holland et al., 1991) and it 
was utilized with fluorescent and quencher dyes by Livak et al. (Livak et al., 1995). In 
the TaqMan probe-based approach, the probe contains one fluorophore (6-carboxy-
fluoroscein) at its 5′ terminus and a quencher (6-carboxytetramethyl- rhodamine; 
TAMRA) at its 3′ terminus. When in close proximity, the two dyes formed a quenched 
system and no fluorescence was observed. However, when the probe hybridized to its 
template, the 5′exonuclease activity of the Taq polymerase would hydrolyse the probe 
during PCR amplification.  Once the fluorophores were separated from the quencher, the 
emissions of the fluorophore were no longer being quenched and fluorescence was 
detected (Figure 5). The cycle number at which the real-time fluorescence signals is 
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detected represents the progression of the PCR reaction and is used as an indicator of 
successful target amplification (Wilhelm et al., 2001). This cycle number, also known as 
the threshold cycle (CT) is defined as the PCR cycle in which the increase in fluorescence 
generated by the accumulating PCR amplicons exceeds the mean baseline fluorescence 
and is proportional to the number of target copies present in the sample (Gibson et al., 
1996; Jung et al., 2000). Thus, the development of real-time PCR also allows true 
quantitation of the target nucleic acids. Quantitation of real-time PCR can be performed in 
two ways - relative quantitation and absolute quantitation. Relative quantitation describes 
changes in the amount of a target sequence compared with its level in a related matrix. 
Generally, relative quantitation provides sufficient information and is simpler to develop. 
On the other hand, absolute quantitation states the exact number of nucleic acid targets 
present in the sample, based on the CT of the sample which can then be compared with 
similar data collected from a series of standards by the calculation of a standard curve 
(Freeman et al., 1999). 
 
LDA is a 384-well micro fluidic card that enables 384 simultaneous real-time PCR 
reactions, determining the expression of multiple, user-defined gene clusters (Figure 6).  
This array allows for 1 to 8 samples to be run in parallel against 12 to 384 gene 
expression targets that are pre-loaded into each well on the card. The reproducibility of 
LDA have also been demonstrated and results were compatible with the conventional 






Figure 5: Diagram illustrating the concepts for the TaqMan probe assay. When in close 
proximity, the reporter dye (R) and the quencher (Q) formed a quenched system and no 
fluorescence is observed. Upon exonuclease digestion during the PCR reaction, the 
fluorigenic dye is released from the close proximity of the quencher dye and is hence able 









Figure 6: TaqMan® LDA. (A) Plate layout; (B) LDA format of 96 genes (Format 96a). 
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1.5.2 Regulation patterns of genes in response to 5FU treatment 
Tumor resistance to 5FU may manifest at the start of chemotherapy or develop during 
treatment. Alteration in gene regulation after exposure to 5FU could be the key to 5FU 
resistance. It has been shown that 5FU treatment for 24 hours in resistant cell lines 
resulted in p53 accumulation, up-regulation of p53-target genes on DNA damage 
response, cell cycle regulation and apoptotic pathway (De Angelis et al., 2006). Another 
gene expression analysis identified genes like PDF, CCNG2, AVEN, SSAT and JAG1 to 
be consitutively dysregulated in 5FU resistant cells and transiently altered following 5FU 
exposure for  0, 6, 12 and 24 hours (Boyer et al., 2006).  
 
Multi-timepoint temporal gene expression analysis following 5FU treatment could offer 
insights into understanding the 5FU effects on gene regulation and identifying sets of 
genes responsible for these changes. By comparing the regulation patterns of genes in 
5FU resistant and sensitive samples, we could possibly identify genes that govern 5FU 
resistance if there is distinctive difference in their respective regulation patterns.   
 
1.5.3 RNA interference (RNAi) 
RNA interference (RNAi) is a defense strategy which was first described in 
Caenorhabditis elegans (Fire et al., 1998). It is a sequence-specific, post-transcriptional 
gene silencing process initiated by double-stranded RNA (dsRNA) molecules (Fire et al., 
1998; Figure 7). These dsRNAs are first cleaved by Dicer to produce functional siRNAs 
(19-23 nucleotides long). Subsequently, these siRNAs are loaded into the RNA-induced 
silencing complex (RISC), which contains helicase that unwinds the duplex (Nykanen et 
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al., 2001). The siRNA strands direct the RISC to the target mRNA and cleave the 
complementary mRNA. The mRNA is rapidly degraded, resulting in reduction or 
blocking of protein expression.  
 
RNAi technology has been widely applied in cancer research and treatment (Martin et al., 
2007, Bruserud et al., 2007). There are many advantages of using siRNA over other 
methods, such as chemical inhibitors and dominant negative mutants, to knockdown gene 
expression. First of all, virtually any gene can be silenced by siRNA which is highly 
specific. On the contrary, there are not many chemical inhibitors available for gene 
silencing and most of them are non-specific. Direct comparison of an optimized 
phosphorothioate-modified ASO with a siRNA directed against the same target mRNA 
site found that the siRNA was approximately 100 to 1000-fold more efficient (Bertrand et 
al., 2002). Second, the synthesis of siRNA is more straight-forward and less time 
consuming than constructing dominant negative mutants. Lastly, siRNA silencing is more 
specific and has longer sustained silencing than chemical inhibitors and dominant 
negative mutants (Bertrand et al., 2002). This could be due to the protection of the 
siRNAs from intracellular degradation by its incorporation into the RISC. 
  
Although siRNA is highly specific, there are off-target effects which need to be 
minimized in order to have a meaningful siRNA application. Off-target effects can be 
divided into two types of responses: (a) the induction of nonsequence-specific silencing 
pathways via Type 1 Interferon pathway and (b) the silencing of targets that have partial 















Figure 7: The RNA Interference pathway. Long double-stranded RNA (dsRNA) is 
cleaved by the RNase III family member, Dicer, into small interfering RNAs (siRNAs) in 
an ATP-dependent reaction. These siRNAs are then incorporated into the RNA-induced 
silencing complex (RISC). The single-stranded antisense strand guides RISC to 
messenger RNA that has a complementary sequence, which results in the endonucleolytic 




1.6 Scope of Study 
The overall aim of this study is to identify and validate determinants of 5FU sensitivity 
based on a comprehensive examination of genes involved in its transport, metabolism and 
activity (Figure 8). The specific aims are: 
 
1. To rank genes (or combinations thereof) involved in 5FU transport, metabolism and 
activity according to their association with 5FU sensitivity in cell lines, xenografts and 
human tissue samples 
Hypothesis: Expression levels of genes involved in 5FU transport, metabolism and 
activity influence overall cellular 5FU sensitivity. By ranking the genes (or combinations 
thereof) according to strength and consistency of association with 5FU sensitivity in cell 
lines, xenografts and human tissue samples, the strongest determinants of 5FU sensitivity 
can be prioritized for further investigation. 
 
2. To characterize how modulation of expression of prioritized genes affects 5FU 
sensitivity in vitro 
Hypothesis: Modulation of the expression of genes that have a determining role in 5FU 







igure 8: Genes analyzed in this study for their roles in transport and metabolism of 5FU and its downstream
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5FU: 5-fluorouracil; 5-Fo-THF: 5-Formimino-THF; 5-Fm-THF: 5-formyl-THF; 10-Fm-THF: 10-formyl-
THF; 5-met-THF: 5-methyl-THF; 5,10-met-THF: 5,10-methenyl-THF; 5,10-metn-THF: 5,10-methylene-
THF; (F): Fluoro; ABCC4: ATP-binding cassette, sub-family C, member 4; ABCC5: ATP-binding cassette, 
sub-family C, member 5; ABCC11: ATP-binding cassette, sub-family C, member 11; ABCC12: ATP-
binding cassette, sub-family C, member 12; AK3: Adenylate kinase 3; ALDH1L1: Aldehyde 
dehydrogenase I family, member L1; AMT: Aminomethyltransferase; ATIC: 5’-aminoimidazole-4-
carboxamide ribonucleotide formyltransferase; ATR: Ataxia telangiectasia and Rad3 related; ATM: Ataxia 
telangiectasia mutated homolog; BAL: β-alanine; bcl-2: B-cell CLL/lymphoma 2; CANT1: Calcium 
activated nucleotidase I; CDA: Cytidine deaminase; CHEK1: CHK1 checkpoint homolog; CHEK2: CHK2 
checkpoint homolog; CMP: Cytidine monophosphate CDP: Cytidine diphosphate CTP: Cytidine 
triphosphate; CTPS: CTP synthase; Cyd: Cytidine; DHF: Dihydrofolate; DHFR: DHF reductase; DPYS: 
Dihydropyrimidinase; DPYD: Dihydropyrimidine dehydrogenase; dUDP: Deoxyuridine diphosphate; 
dUMP: Deoxyuridine monophosphate; DUT: dUTP pyrophosphatase; dUTP: Deoxyuridine triphosphate; 
dUrd: Deoxyuridine; dTMP: Deoxyuridine triphosphate; DTYMK: Deoxythymidylate kinase; dUMP: 
Deoxyuridine monophosphate; ENTPD: Ectonucleoside triphosphate diphosphohydrolase; Exo1: 
Exonuclease 1; FTCD: Formiminotransferase cyclodeaminase; GART: Phosphoribosylglycinamide 
formyltransferase; HMGB1: High-mobility group box 1; MLH1: mutL homolog 1; MSH2: mutS homolog 
2; MSH6: mutS homolog 6; MTFMT: Mitochondrial methionyl-tRNA formyltransferase; MTHFD: 
Methylenetetrahydrofolate dehydrogenase; MTHFD1L: Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) I-like; MTHFR: 5,10-methylenetetrahydrofolate reductase (NADPH); MTHFS: 5,10-
methenyltetrahydrofolate synthetase; MTR: 5-methyltetrahydrofolate-homocysteine methyltransferase; 
NME: Non-metastatic cells; NT: Nucleotidase; NUDT2: Nudix (nucleoside diphosphate linked moiety X)-
type motif 2; PARP-1: Poly (ADP-ribose) polymerase 1; PARP-2: Poly (ADP-ribose) polymerase 2; 
Postmeiotic segregation increased 2; RRM: Ribonucleotide reductase; SHMT: Serine 
hydroxymethyltransferase; SLC28A1: Solute carrier family 28, member 1; SLC28A2: Solute carrier family 
28, member 2; SLC28A3: Solute carrier family 28, member 3; SLC29A1: Solute carrier family 29, member 
1; SLC29A2: Solute carrier family 29, member 2; SLC29A3: Solute carrier family 29, member 3; 
SLC29A4: Solute carrier family 29, member 4; SMUG1: Single-strand-selective monofunctional uracil-
DNA glycosylase 1; THF: Tetrahydrofolate; TK: Thymidine kinase; TP: Thymidine phosphorylase; TP53: 
Tumor protein p53; TS: Thymidylate synthase; TXNRD: Thioredoxin reductase; TYMP: Thymidine 
phosphorylase; UCK: Uridine-cytidine kinase; Urd: Uridine; UDP: Uridine diphosphate; UMP: Uridine 
monophosphate; UMPS: Uridine monophosphate synthetase; UNG: Uracil-DNA glycosylase; UTP: 
Uridine triphosphate; UPB1: β-ureidopropinase; UppppU: P1,P4-Bis(5'-uridyl) tetraphosphate; XRCC1: X-
ray repair complementing defective repair in Chinese hamster cells 1 
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CHAPTER 2: MATERIALS AND METHODS  
 
2.1 Cell lines 
Twenty one colorectal cancer cell lines of human origin were investigated. Caco-2, 
Colo201, Colo205, Colo320DM, DLD-1, HCT116, HT29, LoVo, LS513, LS174T, RKO, 
SW403, SW480, SW620, SW837 and WiDR were obtained from American Type Culture 
Collection (ATCC, Rockville, MD). CCK-81, CoCM-1, HCC56, OUMS23 and RCM1 
were obtained from Japanese Collection of Research Bioresources (Osaka, Japan). Cells 
were routinely cultured in DMEM or RPMI1740 supplemented with 10% fetal bovine 
serum (Invitrogen, Madison), 50,000 units penicillin and 50mg streptomycin (Sigma, St 
Louis, MO) at 37°C in a humidified atmosphere containing 5% CO2.  
 
2.2 Cell sensitivity analysis 
Cells were seeded in 100 µl medium onto 96-well microtitration plates (Nunc, Rochester, 
NY) with an initial cell density of 5000 per well. After 24 hours, 100 µl of medium 
containing 5FU (Sigma) with graded concentrations ranging from 0.01 µM to 1000 µM 
was added to the wells and cells were incubated for another 48 hours. Cytotoxicity was 
assessed by methyl thiazolyltetrazolium (MTT)-based CellTiter 96® Non-Radioactive 
Cell Proliferation assay (Promega, Madison, WI) according to manufacturer’s 
instructions and analyzed at 570 nm. All investigations were performed in triplicates. IC50 
values were determined from curves plotted according to the dose-response function of 
GraphPad Prism software (GraphPad Software Inc., San Diego, CA). 
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2.3 Xenografts 
Fourteen colon carcinoma xenografts were kindly provided by Dr. Iduna Fichtner at the 
Max-Delbrück-Center for Molecular Medicine Berlin-Buch (Berlin, Germany). The 
antitumor activity of 5FU in the 14 xenografts has been previously characterized 
(Fitchner et al., 2004). Non-response to 5FU was defined as tumor shrinkage of less than 
50% after drug treatment. 
 
2.4 Primary Tumors 
Total RNA and clinicopathological data of 25 stage II/III colorectal frozen tumors of 
patients treated with 5FU-based chemotherapy was kindly provided by NUH-NUS Tissue 
Repository, Singapore under protocols approved by the Institutional Review Board, 
National University of Singapore. Tumor RNA provided was extracted from whole 
human tissue of tumor content ≥50% using the TRI reagent (MRC, Cincinnati, OH, USA) 
according to manufacturer’s instructions. Twelve patients were females and 13 were 
males, with ages ranging from 45 to 82 year-old (median 62). Four cases were stage II 
disease. Treatment consisted of standard 5FU and leucovorin administration for at least 1 
cycle after tumor resection. Lack of response to 5FU treatment is defined as recurrence 
within 5 years. 
 
2.5 Gene expression analysis 
A total of 92 genes involved in the pyrimidine and folate metabolism were identified 
from Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database 
(http://www.genome.ad.jp/kegg/pathway.html), whereas those in the transport and 
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downstream mechanisms were obtained from literature review (Table 3). Four 
housekeeping genes (18s, ACTB, B2M and GAPDH) were also included into the assay.  
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Table 3: List of 96 genes selected for LDA analysis. 
Gene symbol Gene name Alias GenBank 
Accession No. 
References 
     
Housekeeping 
genes 
    
18S 18S ribosomal RNA - X03205.1 Banda et al., 
2008 
ACTB Actin, beta - NM_001101.3 Banda et al., 
2008 




- NM_002046.3 Banda et al., 
2008 
     
Transporters     
ABCC4 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 4 
MRP4 NM_005845.3 
 
Borst et al., 
2007 
ABCC5 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 5 
MRP5 NM_005688.2 Pratt et al., 
2005 
ABCC11 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 11 
MRP8 NM_032583.3 
 
Guo et al., 
2003 
ABCC12 ATP-binding cassette protein C12; ATP-
binding cassette transporter sub-family C 
member 12 
MRP9 NM_033226.2 Yabuuchi et 
al., 2001 
SLC28A1 Solute carrier family 28 (sodium-coupled 





SLC28A2 Solute carrier family 28 (sodium-coupled 





SLC28A3 Solute carrier family 28 (sodium-coupled 
nucleoside transporter), member 3 
CNT3 NM_022127.1 
 
Ritzel et al., 
2001 
SLC29A1 Solute carrier family 29 (nucleoside 





SLC29A2 Solute carrier family 29 (nucleoside 





SLC29A3 Solute carrier family 29 (nucleoside 





SLC29A4 Solute carrier family 29 (nucleoside 
transporters), member 4 
ENT4 NM_153247.2  
     
Metabolism 
(pyrimidine) 
    
AK3 Adenylate kinase 3 AK6 NM_016282.2 Kegg 
(pyrimidine) 
CANT1 Calcium activated nucleotidase I ENTPD8 NM_138793.2 Kegg 
(pyrimidine) 
CDA Cytidine deaminase CDD NM_001785.2 Kegg 
(pyrimidine) 
CES1 Carboxylesterase 1 ACAT NM_001266.4 Kegg 
(pyrimidine) 
CES2 Carboxylesterase 2 CE-2 NM_003869.4 Kegg 
(pyrimidine) 
CTPS CTP synthase - NM_001905.2 Kegg 
(pyrimidine) 
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CTPS2 CTP synthase II - NM_019857.3 Kegg 
(pyrimidine) 
DPYD Dihydropyrimidine dehydrogenase DPD NM_000110.3 Kegg 
(pyrimidine) 
DPYS Dihydropyrimidinase DHPase NM_001385.2 Kegg 
(pyrimidine) 
DTYMK Deoxythymidylate kinase TYMK NM_012145.2 Kegg 
(pyrimidine) 
DUT dUTP pyrophosphatase dUTPase NM_001948.3 Kegg 
(pyrimidine) 




























ENTPD6 Ectonucleoside triphosphate 
diphosphohydrolase 6 
ITPase NM_001247.2 Kegg 
(pyrimidine) 
ITPA Inosine triphosphatase NM23-H1 NM_181493.1 Kegg 
(pyrimidine) 
NME1 Non-metastatic cells 1 NM23-H2 NM_000269.2 Kegg 
(pyrimidine) 
NME2 Non-metastatic cells 2 NM23-H3 NM_002512.2 Kegg 
(pyrimidine) 
NME3 Non-metastatic cells 3 NM23-H4 NM_002513.2 Kegg 
(pyrimidine) 
NME4 Non-metastatic cells 4 NM23-H5 NM_005009.2 Kegg 
(pyrimidine) 
NME5 Non-metastatic cells 5 NM23-H6 NM_003551.2 Kegg 
(pyrimidine) 
NME6 Non-metastatic cells 6 NM23-H7 NM_005793.3 Kegg 
(pyrimidine) 
NME7 Non-metastatic cells 7 PNP NM_013330.3 Kegg 
(pyrimidine) 
NP Nucleoside phosphorylase DNT NM_000270.2 Kegg 
(pyrimidine) 
NT5C 5’,3’-nucleotidase, cytosolic CN1A NM_014595.1 Kegg 
(pyrimidine) 
NT5C1A 5’-nucleotidase, cytosolic IA CN1B NM_032526.1 Kegg 
(pyrimidine) 
NT5C1B 5’-nucleotidase, cytosolic IB GMP NM_033253.2 Kegg 
(pyrimidine) 
NT5C2 5’-nucleotidase, cytosolic II UMPH NM_012229.2 Kegg 
(pyrimidine) 




NT5E 5’-nucleotidase, ecto (CD73) dNT-2 NM_002526.1 Kegg 
(pyrimidine) 
NT5M 5’,3’-nucleotidase, mitochondrial APAH1 NM_020201.3 Kegg 
(pyrimidine) 
NUDT2 Nudix (nucleoside diphosphate linked 
moiety X)-type motif 2 
PNPASE NM_001161.3 Kegg 
(pyrimidine) 
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PNPT1 Polyribonucleotide nucleotidyltransferase 
1 
R1 NM_033109.2 Kegg 
(pyrimidine) 
RRM1 Ribonucleotide reductase M1 polypeptide R2 NM_001033.3 Kegg 
(pyrimidine) 
RRM2 Ribonucleotide reductase M2 polypeptide p53R2 NM_001034.1 Kegg 
(pyrimidine) 
RRM2B Ribonucleotide reductase M2 B - NM_015713.3 Kegg 
(pyrimidine) 
TK1 Thymidine kinase 1 - NM_003258.4 Kegg 
(pyrimidine) 
TK2 Thymidine kinase 2 TR1 NM_004614.3 Kegg 
(pyrimidine) 
TXNRD1 Thioredoxin reductase 2 TR3 NM_003330.2 Kegg 
(pyrimidine) 
TXNRD2 Thioredoxin reductase 2 TP NM_006440.3 Kegg 
(pyrimidine) 
TYMS Thymidylate synthase  TS NM_001071.1 Kegg 
(pyrimidine) 
UCK1 Uridine-cytidine kinase 1 URK1 NM_031432.1 Kegg 
(pyrimidine) 
UCK2 Uridine-cytidine kinase 2 UK NM_012474.3 Kegg 
(pyrimidine) 
UMPS Uridine monophosphate synthetase OPRT NM_000373.2 Kegg 
(pyrimidine) 
UPB1 Ureidopropinase, beta BUP1 NM_016327.2 Kegg 
(pyrimidine) 
UPP1 Uridine phosphorylase 1 UP NM_181597.1 Kegg 
(pyrimidine) 
UPP2 Uridine phosphorylase 2 UP2 NM_173355.2 Kegg 
(pyrimidine) 
     
Metabolism 
(folate) 
    
ALDH1L1 Aldehyde dehydrogenase I family, 
member L1 
FTHFD NM_012190.2 Kegg 
(folate) 




AICAR NM_004044.4 Kegg 
(folate) 
DHFR Dihydrofolate reductase - NM_000791.3 Kegg 
(folate) 




PRGS NM_000819.3 Kegg 
(folate) 
MTFMT Mitochondrial methionyl-tRNA 
formyltransferase 
FMT1 NM_139242.3 Kegg 
(folate) 
MTHFD1 Methylenetetrahydrofolate dehydrogenase DCS NM_005956.2 Kegg 
(folate) 
MTHFD1L Methylenetetrahydrofolate dehydrogenase 





MTHFD2 Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 
NMDMC NM_006636.3 Kegg 
(folate) 
MTHFR 5,10-methylenetetrahydrofolate reductase 
(NADPH) 
- NM_005957.3 Kegg 
(folate) 
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MS NM_000254.2 Kegg 
(folate) 
SHMT1 Serine hydroxymethyltransferase 1 
(soluble) 
CSHMT NM_004169.3 Kegg 
(folate) 
SHMT2 Serine hydroxymethyltransferase 2 GYLA NM_005412.4 Kegg 
(folate) 





    
ATM Ataxia telangiectasia mutated homolog AT1 NM_000051.3 Yu et al., 
2006
ATR Ataxia telangiectasia and Rad3 related FRP1 NM_001184.3 Yu et al., 
2006
bcl2 B-cell CLL/lymphoma 2 Bcl-2 NM_000633.2 Christmann 
et al., 2003 
CHEK1 CHK1 checkpoint homolog Chk1 NM_001274.4 Christmann 
et al., 2003
CHEK2 CHK2 checkpoint homolog Chk2 NM_007194.3 Christmann 
et al., 2003
Exo1 Exonuclease 1 HEX1 NM_003686.3 Christmann 
et al., 2003 
HMGB1 High-mobility group box 1 HMG1 NM_002128.4 Yu et al., 
2006 
MLH1 mutL homolog 1, colon cancer, 
nonpolyposis type 2 
HNPCC2 NM_000249.2 Yu et al., 
2006 
MSH2 mutS homolog 2, colon cancer, 
nonpolyposis type 1 
HNPCC1 NM_000251.1 Yu et al., 
2006 
MSH6 mutS homolog 6 HNPCC5 NM_000179.2 Yu et al., 
2006 
PARP-1 Poly (ADP-ribose) polymerase 1 ADPRT NM_001618.3 Christmann 
et al., 2003 
PARP-2 Poly (ADP-ribose) polymerase 2 ADPRT2 NM_005484.3 Christmann 
et al., 2003 
PMS2 Postmeiotic segregation increased 2 HNPCC4 NM_000535.4 Christmann 
et al., 2003 
SMUG1 Single-strand-selective monofunctional 
uracil-DNA glycosylase 1 
UNG3 NM_014311.1 Christmann 
et al., 2003 
TP53 Tumor protein p53 p53 NM_000546.3 Yu et al., 
2006 
UNG Uracil-DNA glycosylase UDG NM_003362.2 Christmann 
et al., 2003 
XRCC1 X-ray repair complementing defective 
repair in Chinese hamster cells 1 
RCC NM_006297.1 Yu et al., 
2006 
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Total RNA was extracted from the respective cell lines and whole tumor xenograft 
tissues using the TRI reagent (MRC) according to manufacturer’s instructions. Total 
RNA yields and purity were determined spectrophotometrically at 260 and 280 nm. Real-
time RT-PCR was carried out using the Low Density Array (LDA) system (Applied 
Biosystems, Foster City, CA), preloaded with inventoried TaqMan® Gene Expression 
Assays into 384-well micro-fluidic cards, according to the manufacturer’s instructions. In 
brief, 1µg of total RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The reaction mixtures were incubated at 25°C 
for 10 min, followed by 37°C for 120 min and 95°C for 5 min. Nine µl of cDNA samples 
(equivalent to 400 ng of total RNA), along with 41 µl of nuclease-free water and 50 µl of 
2 × PCR master mix, were loaded into each sample port on the micro-fluidic card. 
Thereafter, the card was centrifuged twice for 1 min at 331 x g at room temperature and 
then sealed. Real-time PCR and relative quantification were performed using an ABI 
PRISM 7900 HT Sequence Detection System. The expression values of target gene were 
normalized to GAPDH levels using SDS 2.2.1 software (Applied Biosystems). 
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2.6 Small interfering RNA (siRNA) transfections 
Pre-designed Silencer Select siRNA (CTPS2, sense strand: 5’-
GGUUCGAGGUAAACCCUAATT-3’ and antisense strand: 5’-
UUAGGGUUUACCUCGAACCGA-3’; GAPDH, sense strand: 5'-
GGUCAUCCAUGACAACUUUTT-3' and antisense strand: 5'-
AAAGUUGUCAUGGAUGACCTT-3; Negative Controls, sense strand: 5’-
UAACGACGCGACGACGUAATT-3’ and antisense strand: 5’-
UUACGUCGUCGCGUCGUUATT-3’) were purchased from Applied Biosystems. 
SW620 cells were transfected with CTPS2 siRNA (5 nM) or GAPDH siRNA (10 nM) or 
negative controls  using siPORT NeoFX transfection agent (Applied Biosystems) at 50% 
cell confluence incubated in serum-free Opti-MEM I medium (Invitrogen) according to 
the manufacturer’s instructions. Cells were treated with 10 μM of 5FU 48 hours after 
transfection. To measure the number of viable cells, cells were stained with Trypan blue 
solution (Promega) at 24, 48 and 72 hours after 5FU treatment. Experiments were done in 
duplicate.  
 
2.7 Statistical analysis 
Using statistical software R version 2.7.1 (R Foundation for Statistical Computing, 
Vienna, Austria), unsupervised hierarchical clustering analysis was carried out to 
examine gene expression relationships and to identify sample groupings in each series. 
The function heatmap.2 in library gplots within R version 2.7.1 was used for the heatmap 
and cluster generation. The default distance/dissimilarity matrix was used, which equates 
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to the Euclidean distance measure. Multiple testing correction was performed by 
Bonferroni correction.  
 
Two-sample t-test was used to identify differentially expressed gene between sample 
groupings with significance of p<0.05. Gene expression analysis over time was carried 
out for RKO and SW837 using Short Time-series Expression Miner (STEM) software 
(Ernst et al., 2006) to identify significant temporal expression profiles and the genes 









Figure 9: A schema of analyses done in the 3 series (cell lines, xenografts and patients) in 
identifying determinants of 5FU sensitivity. 
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CHAPTER 3: RESULTS 
3.1 Correlation between gene expression and 5FU sensitivity 
To determine if 5FU sensitivity correlates with gene expression in the first instance, 
unsupervised hierarchical clustering analysis was performed separately on cell line, 
xenograft and primary tumor RNA levels. For cell lines, a wide range of 5FU IC50 values 
(0.7-32.7 µM) were observed (Table 4a), however there was no correlation between 5FU 
sensitivity and gene expression (Figure 10A). This was the case either using a cut-off for 
sensitivity of 10 µM (Rossi et al. 2007), 7.91 µM (median) or 8.95 µM (mean). 
Nevertheless, related cell lines such as HT29 and WiDR (ATCC), SW480 and SW620 
(ATCC), as well as COLO201 and COLO205 (ATCC), grouped together, supporting the 
accuracy of the clustering analysis.  
 
The characterization of 5FU sensitivity in xenografts is reported in Table 4b. Xenograft 
cases clustered into three major groups (Figure 10B), for which one group (I) of 4 cases 
consisted entirely (100%) of responders, while only 2/9 (22%) cases in the other group 
were responders (p=0.02). Xenograft sample 5854 clustered alone, indicating it to be an 
outlier. As a result, this case was not included in subsequent analysis.  
 
5FU sensitivity in primary tumors characterized as tumor recurrence within 5 years is 
shown in Table 4c. In primary tumors, gene expression patterns also displayed a trend for 
correlation with 5FU response (Figure 10C). In one major group (I), all 4/4 (100%) cases 
were responders, while only 17/21 (71%) cases were responders in the other major group 
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(II) (p>0.05).  There was no significant difference in age, sex and tumor stage between 






Table 4: Characterization of 5FU sensitivity: (A) IC50 values of 21 colorectal cancer cell 
lines; (B) % of tumor shrinkage in 14 xenografts treated by 5FU; (C) Recurrence data of 
25 stage II or III colorectal cancer patients treated with standard 5FU and leucovorin 




Cell Line IC50 ± S.D. (μM) 
Caco-2 5.6 ± 1.6 
CCK81 5.0 ± 1.3 
CoCMI 9.8 ± 1.5 
Colo201 8.5 ± 1.5 
Colo205 12.2 ± 1.5 
Colo320 3.4 ± 1.4 
DLD-1 2.2 ± 1.4 
HCC56 17.6 ± 1.3 
HCT116 8.0 ± 1.1 
HT29 7.9 ± 1.3 
LoVo 3.1 ± 1.4 
LS174T 4.4 ± 1.4 
LS513 13.1 ± 1.5 
OUMS23 0.7 ± 2.7 
RCM1 9.5 ± 1.6 
RKO 19.5 ± 1.4 
SW403 32.7 ± 1.3 
SW480 7.2 ± 1.5 
SW620 9.3 ± 1.3 
SW837 0.7 ± 2.1 






Xenograft Tumor shrinkage 5FU sensitivity 
5676 + R 
5677 – NR 
5679 – NR 
5682 + R 
5734 + R 
5735 + R 
5771 + R 
5776 – NR 
5841 – NR 
5854 – NR 
5896 – NR 
6044 – NR 
6228 – NR 
7271 + R 
  
a + indicates ≥50% tumor shrinkage 





Tumor Recurrence 5FU sensitivity 
NT00/0008 – R 
NT00/0025 + NR 
NT00/0031 – R 
NT00/0068 – R 
NT00/0076 – R 
NT00/0126 – R 
NT00/0137 – R 
NT00/0160 – R 
NT00/0189 – R 
NT01/0005 – R 
NT01/0007 – R 
NT01/0019 – R 
NT01/0035 – R 
NT01/0057 – R 
NT02/0012 – R 
NT02/0019 – R 
NT02/0028 – R 
NT02/0048 – R 
NT02/0049 – R 
NT02/0060 – R 
NT02/0062 – R 
NT02/0094 + NR 
NT03/0014 – R 
NT03/0048 + NR 
NT04/0099 + NR 
  
a + indicates tumor recurrence within 5 years 
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Table 5: Associations (χ2 test) between 5FU sensitivity and clinicopathological 
parameters. ‘R’ refers to responder and ‘NR’ refers to non-responder. 
 
  Total (%) 5FU sensitivity (%) p 
    R NR   
All cases 25 (100%) 21 (84%) 4 (16%)  
     
Age, y    1.0
<50 3 (12%) 3 (100%) 0 (0%)  
≥50 22 (68%) 18 (82%) 4 (18%)  
     
Sex    1.0
Female 12 (48%) 10 (83%) 2 (17%)  
Male  13 (52%) 11 (85%) 2 (15%)  
     
Stage    0.5
II 4 (16%) 3 (75%) 1 (25%)  
III 21 (84%) 18 (86%) 3 (14%)  




3.2 Identification of baseline gene expression associated with 5FU sensitivity 
Since the cell line groupings did not correspond with their sensitivity to 5FU, thus, no 
candidate gene was derived from this series. Using a two-sample t-test, 8 out of 96 genes 
showed significant difference in expression between the 2 main clusters in xenografts 
(Table 6). For primary tumors, the expression of 41 genes was significantly different. 
Two genes, cytidine triphosphate synthase type II (CTPS2) and non-metastatic cells 4 
(NME4) were present in both lists and hence were considered the top priority candidate 
determinants of 5FU sensitivity. Indeed, CTPS2 and NME4 expression was higher in 
responders than non-responders in both xenografts and primary tumors and the difference 








Table 6: Candidate genes with differential gene expression (p<0.05) identified by two 
sample t-test for xenografts and primary tumors. Genes that occur in both lists of 
xenografts and primary tumors are highlighted in bold.  
 




     
Xenografts     
ACTB Actin, beta 5.6 <0.01 1.98 
18S 18S ribosomal RNA 3.2 0.01 4.57 
CANT1 Calcium activated nucleotidase I 3.0 0.01 0.54 
MSH6 mutS homolog 2, colon cancer, 
nonpolyposis type 1 2.7 0.02 1.29 
NME4 Non-metastatic cells 4 2.6 0.02 1.69 
CTPS2 CTP synthase II 2.4 0.03 2.25 
NT5C 5’,3’-nucleotidase, cytosolic 2.3 0.04 2.19 
PARP1 Poly (ADP-ribose) polymerase 1 2.4 0.04 1.98 
    
 
Primary 
Tumours    
 
B2M Beta-2-microglobulin 11.5 <0.01 0.17 
TXNRD1 Thioredoxin reductase 1 8.7 <0.01 0.31 
NT5E 5’-nucleotidase, ecto (CD73) 6.3 <0.01 0.13 
ECGF1 Thymidine phosphorylase 6.0 <0.01 0.25 
UCK1 Uridine-cytidine kinase 1 5.5 <0.01 0.32 
ABCC4 ATP-binding cassette, sub-
family C (CFTR/MRP), member 
4 4.7 <0.01 0.26 
RRM1 Ribonucleotide reductase M1 
polypeptide 4.6 <0.01 0.37 
ENTPD1 Ectonucleoside triphosphate 
diphosphohydrolase 1 4.2 <0.01 0.13 
MTFMT Mitochondrial methionyl-tRNA 
formyltransferase 4.2 <0.01 0.40 
UPB1 Ureidopropinase, beta 4.1 <0.01 0.15 
ATM Ataxia telangiectasia mutated 
homolog 4.0 <0.01 0.21 
MTHFR 5,10-methylenetetrahydrofolate 
reductase (NADPH) 4.0 <0.01 0.29 
CES1 Carboxylesterase 1 4.0 <0.01 0.16 
DPYS Dihydropyrimidinase 3.8 <0.01 0.07 
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ENTPD3 Ectonucleoside triphosphate 
diphosphohydrolase 3 3.8 <0.01 0.16 
BCL2 B-cell CLL/lymphoma 2 3.8 <0.01 0.26 
PARP2 Poly (ADP-ribose) polymerase 2 3.7 <0.01 0.32 
DPYD Dihydropyrimidine 
dehydrogenase 3.6 <0.01 0.16 
NT5C3 5’-nucleotidase, cytosolic III 3.6 <0.01 0.23 
RRM2B Ribonucleotide reductase M2 B 3.5 <0.01 0.44 
NME3 Non-metastatic cells 3 3.4 <0.01 0.28 
ALDH1L1 Aldehyde dehydrogenase I 
family, member L1 3.4 <0.01 0.34 
NUDT2 Nudix (nucleoside diphosphate 
linked moiety X)-type motif 2 3.4 <0.01 0.30 
MTHFD2 Methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 3.2 <0.01 0.38 
CTPS2 CTP synthase II 3.1 <0.01 0.40 
NME5 Non-metastatic cells 5 6.3 0.01 0.29 
SLC28A3 Solute carrier family 28 
(sodium-coupled nucleoside 
transporter), member 3 3.0 0.01 0.34 
ENTPD4 Ectonucleoside triphosphate 
diphosphohydrolase 4 3.0 0.01 0.32 
CHEK2 CHK2 checkpoint homolog 2.9 0.01 0.45 
DHFR Dihydrofolate reductase 2.7 0.01 0.55 
NME7 Non-metastatic cells 7 2.7 0.01 0.41 
MSH2 mutS homolog 2, colon cancer, 
nonpolyposis type 1 2.7 0.02 0.50 
NME4 Non-metastatic cells 4 2.6 0.02 0.34 
NME6 Non-metastatic cells 6 2.5 0.02 0.47 
TK2 Thymidine kinase 2 2.5 0.02 0.33 
UPP2 Uridine phosphorylase 2 2.4 0.03 0.06 
ATR Ataxia telangiectasia and Rad3 
related 2.4 0.03 0.36 
MLH1 mutL homolog 1, colon cancer, 
nonpolyposis type 2 2.3 0.03 0.47 
CES2 Carboxylesterase 2 2.3 0.03 0.19 






































































Figure 11: Difference in expression levels of CTPS2 and NME4 between clusters in (A) 




3.3 Identification of post-treatment gene expression changes associated with 5FU 
sensitivity 
To identify genes for which expression changes after 5FU treatment best discriminated 
5FU sensitivity from resistance, SW837 (5FU sensitive) and RKO (5FU resistant) cells 
were seeded at an initial density of 1 x 105/ml for 24 hours. Cells were treated with 10 
μM of 5FU for 0, 4, 8, 12, 24 and 48 hours, after which cells were harvested for RNA and 
analyzed for the expression of the selected 96 genes.  
 
Genes with similar expression change patterns were grouped based on Pearson 
correlation coefficient, and these groups ranked according to degree of similarity in 
change patterns (Figure 12). The model profiles (patterns) are generated by the software 
in two steps. Firstly, the system exhaustedly listed all possible patterns according to the 
user parameter c. “c” represents possible stages that a gene can be regulated between time 
points. For example, if c=1, it means that a gene can be up-regulated, down-regulated, or 
unchanged, and if c=2, it means that a gene can be up-regulated for 1 or 2 stages, down-
regulated for 1 or 2 stages or unchanged. Thus, there are in total (2*c+1)n-1, where n is the 
number of time points. The first time point will always be regarded as unchanged.  In our 
experiment, we have set: c=2, n=6. Secondly, the software selected a subset of patterns 
from the exhaustedly generated patterns, promising that the selected patterns are 
representative and distinct from each other, that is, to maximize the minimal distance 
between any of the two patterns.  Since the optimal solution to the second step is Non-
deterministic Polynomial-time Hard (NP-Hard), a heuristic algorithm is proposed by 
Ernst and colleagues (Ernst et al. 2005). 
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The top-ranked patterns were surmised to be the ones that defined sensitivity and 
resistance in the respective cell lines. Interestingly, CTPS2 was identified in the top 
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3.4 Modulation of 5FU sensitivity by CTPS2 siRNA 
To verify the direct influence of CTPS2 on 5FU sensitivity, the effects of siRNA 
knockdown of CTPS2 expression were examined, with GAPDH siRNA treatment as a 
control. 5FU-sensitive cell line (<10 µM) with relatively high CTPS2 levels would be an 
ideal choice for CTPS2 knockdown and measuring the change in 5FU sensitivity. SW620 
as an adherent cell line was chosen for this investigation as its CTPS2 level was fourth 
highest among all 5FU sensitive cell lines. Using chemical transfection agents, siRNA 
transfections of the top 2 cell lines in rank (CCK81, CoCM1) were unsuccessful while 
transfection of Colo201 (third in rank for its CTPS2 level) was not attempted as these 
cells are in suspension. Cell lines grown in suspension culture remain challenging 
transfection targets.  
 
More than 50% reduction of CTPS2 and GAPDH RNA levels was achievable in SW620 
cells following 48 hours treatment with respective siRNA (Figure 13A and 13B), 
although full CTPS2 expression were restored after 120 hours treatment. Cells transfected 
for 48 hours with siRNA were then treated with 10 μM 5FU (IC50 of SW620 at 48 hours) 
and cell viability was measured at 24, 48 and 72 hours. At 48 hours post-5FU treatment, 
viability of CTPS2-knockdown cells was the same as that of transfected cells without 
5FU treatment (Figure 13C), indicating a resistance to 5FU of CTPS2-knockdown cells. 
This result contrasts with that of cells transfected with negative control or GAPDH 
siRNA (Figure 13D and 13E). For these cells, 40-60% reduction in cell growth was 
observed at 48 hours post-5FU treatment, consistent with reduction expected from using 
an IC50 dosage. At 72 hours post 5-FU treatment (120 hours post-siRNA treatment), the 
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number of viable CTPS2-knockdown cells became 53% of non-treated cells. This is 
likely due to the lower CTPS2 knockdown at 120 hours post-siRNA treatment (Figure 













































































































CHAPTER 4: DISCUSSION 
Most investigations on determinants of 5FU sensitivity until now have been candidate 
gene approaches. These have mostly been on genes/proteins involved in the metabolism 
and cytotoxic mechanisms of 5FU, with thymidylate synthase (TS) (Peters et al., 1995) 
and dihydropyrimidine dehydrogenase (DPD) (Diasio et al., 2001) being the most 
prominent. TS has been studied as a major target of 5FU activity, and numerous reports 
have associated elevated TS expression/activity with 5FU resistance (Johnston et al., 
1995, Berger et al., 1985, Clarke et al., 1987, Johnston et al., 1992). DPD is the rate-
limiting step in 5FU clearance, and its deficiency has been correlated to 5FU toxicity and 
increased sensitivity (Diasio et al., 1988; Ishikawa et al., 1999; Milano et al., 1999). 
However, not all studies on TS and DPD have been in agreement (Soong and Diasio 
Findlay et al., 1997; Berglund et al., 2002; Allegra et al., 2003; Johnston et al., 2003; 
Kinoshita et al., 2007; Yamada et al., 2008), indicating other factors are involved.  
 
Gene expression profiling has also been applied to identifying determinants of 5FU 
response at a genome-wide level (Scherf et al., 2000; Zembutsu et al., 2002; Mariadason 
et al., 2003; Shimizu et al., 2005; Matsuyama et al., 2006). Testing response to multiple 
drugs on the NCI panel of 60 cell lines, Scherf et al. identified that DPD is highly 
negatively correlated with 5FU response (Scherf et al., 2000). Similar to the NCI panel of 
60 cell lines, the cell lines used in our study were exposed to 5FU for 48 hours. The IC50 
values for the overlapped cell lines from both experiments were similar except for SW620 
which is shown to be more 5FU resistant by Scherf et al. Mariadason et al. studied a 
panel of 30 colon cancer cell lines and identified 420 genes, enriched in DNA replication 
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and repair and protein processing/targeting, to be significantly associated with 5FU 
sensitivity (Mariadason et al., 2003). The 30 colon cancer cell lines described by 
Mariadason et al. were exposed to 5FU for 72 hours. Most of the IC50 values of 
overlapping cell lines reported by Mariadason et al. were similar except for SW480 and 
SW620 which seemed to be more resistant, whilst RKO and SW403 seemed to be more 
sensitive to 5FU.  Moreover, based on the IC50 values, 2 of the four cell lines tested by 
Scherf et al. (Colo205, HCT116) were found to be more sensitive to 5FU than that of 
Mariadason et al. Zembutsu and colleagues examined 9 anticancer agents in 85 cancer 
xenografts and identified 20 novel genes related to 5FU sensitivity (Zembutsu et al., 
2002). Shimizu et al. analyzed 3 colorectal cancer cell lines and corresponding resistant 
sublines and identified 81 genes related to 5FU sensitivity (Shimizu et al., 2005). A 
derivative panel of these genes has since been validated with TNFRS1B, SLC35F5 and 
OPRT identified as a “Response Index” (Matsuyama et al., 2006). 
 
In this study, CTPS2 was identified as a determinant of 5FU sensitivity through an 
integration of pathway-based real-time PCR analysis of three cancer models, an 
examination of both basal and temporal gene expression levels and siRNA knockdown. A 
pathway-based approach, comprising examination of 92 genes in 5FU transport, 
metabolic and downstream activity (Figure 1), was adopted as the candidates identified 
were more likely to have a rational basis for influencing 5FU sensitivity. Real-time PCR 
was used to achieve optimal detection sensitivity, dynamic range and analytical precision, 
as opposed to a hybridization array approach (Wong et al., 2005). Interrogation of cell 
lines, xenografts and primary tumours were used to best identify candidates that were 
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robustly linked to 5FU sensitivity (Figure 10). However, candidate genes were not 
derived from the cell lines as their chemosensitivity did not correspond well with sample 
groupings. The lack of correlation between cell lines and clinical specimens has been 
described previously (Andreotti et al., 1994). The specific 5FU/LV regimen undertaken 
by the patients in this study makes it more valuable as studies which combine patients 
receiving different types of 5FU administration introduce greater variation between 
patients and thus, their findings do not strictly correspond to drug effect (Gustavsson et 
al., 2008). Finally, siRNA knockdowns were used to confirm that reduced CTPS2 
expression directly leads to 5FU resistance (Figure 13). Although the use of one CTPS2 
siRNA sequence might raise concern with off-target effects, it was shown using BLAST 
analysis that the designed siRNA sequence has 100% specificity to the gene of interest, 
i.e. CTPS2, thus minimizing off-target effects. Not more than one siRNA sequence is 
introduced as high concentration of siRNA could potentially lead to induction of alpha- 
and beta-interferon pathway via protein kinase K pathway (Khabar et al., 2003; Garcia et 
al., 2006).  Taken together, these numerous lines of evidence suggest a role for CTPS2 in 
determining 5FU sensitivity. 
 
A major feature of this study is that we have also identified determinants through 
temporal gene expression analysis following 5FU treatment. On the premise that drug 
sensitivity is likely to be influenced by cell responses to treatment, we characterized the 
expression patterns of the 92 pathway-based genes at 6 timepoints over 48 hours in 
extremely sensitive (SW837) and resistant (RKO) cell lines. Multiple timepoints were 
measured as we considered significant information could be missed between traditional 
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two (pre- and post-treatment) timepoint assessments. STEM software has been useful for 
clustering genes of similar regulation patterns across a short time-series (Lulko et al., 
2007; Martinez et al., 2007), and we took this further by identifying the most tightly 
regulated expression patterns (and component genes) in respective cell lines as 
determinants of 5FU sensitivity and resistance. CTPS2 was one of four genes (the others 
were DTYMK, ITPA, UPP1) in the top gene groups of both sensitive and resistant cell 
lines (Figure 12). Interestingly, the level of CTPS2 went up in the sensitive cell line, and 
decreased in the resistant line, consistent with the baseline expression trends.  
 
CTPS2 is one of 2 genes (the other is CTPS) encoding human cytidine triphosphate 
synthase (van Kuilenberg et al., 2000). The enzyme catalyses the rate-limiting conversion 
of uridine triphosphate (UTP) to CTP, that is important for biosynthesis of RNA, DNA 
and lipids. Hence, one possible mechanism for 5FU resistance observed with low CTPS2 
expression could be UTP accumulation occurring due to reduced conversion to CTP. The 
UTP may compete with the incorporation of FUTP into RNA, thereby reducing the RNA-
directed cytotoxic effects of 5FU. However, other scarce data on CTPS2 neither supports 
nor refutes this mechanism, even more so its relationship to 5FU sensitivity. Increased 
activity of human CTP synthase has been observed in leukemias and tumors of liver, lung 
and colon (Kizaki et al., 1980). Whelan et al. showed treatment of CHO cells with ultra-
violet radiation and ethylmethanesulfonate generates CTPS mutations, eliminating its 
feedback regulation by CTP, altering its synthase activity and increasing intracellular 
pools of CTP and dCTP and resistance to 5FU (Whelan et al., 1993). Somatic mutation of 
neither CTPS nor CTPS2 in tumors has been reported so far. It is indeed possible that 
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other mechanisms like loss of heterozygosity or methylation-induced transcriptional 
silencing of CTPS2 to cause inactivation of this gene and lead to tumor resistance to 5FU.   
 
The second potential candidate, NME4, is identified from the basal gene expression 
analysis but not from the timepoint temporal analysis. NME4 is one of the isoforms of 
nucleoside diphosphate kinase (NDPK/Nm23) and encodes for human mitochondrial 
NDPK-D. NDPK is important for the regulation of intracellular nucleotide homeostasis. 
NME4 was found to be overexpressed in colorectal cancer (Hayer et al., 2001). 
Furthermore, high expression of NME4 has been shown to be associated with poor 
prognosis in patients with acute myeloid leukemia (AML) (Kracmarova et al., 2008). 
However, here we observed that relatively high NME4 expression was associated with 
5FU response. This conflicting observation could be explained by the differences in 
treatment and tumor characteristics of colorectal cancer and AML and the different 
endpoint of response and survival. To further validate the role of NME4, functional 
investigations will be carried out.  
 
As compared to earlier studies, CTPS2 has not been identified as a determinant of 5FU 
response, though its role in 5FU sensitivity has been suggested for via the gene 
expression analyses and in-vitro experiments in our study. This difference in observations 
could be due to the use of different types of samples (cell lines/ xenografts/ human 
paraffin/ frozen tissues; tumor content) and various experimental approaches (DNA/ 
RNA/ protein analyses; RNA analysis using microarray/ real-time PCR). One limitation 
of our study is sample bias, with only few 5FU-resistant patient tumors being analyzed. 
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Continual effort in developing tumor banks of fresh frozen tissue and maintain proper 
documentation of clinical follow up is of utmost importance in order to complement the 
currently available profiling technologies. When more tumors become available, these 
samples could contribute to the validation set for future profiling experiments to validate 
the role of CTPS2.  
 
As in some previous studies, TYMS expression did not associated with 5FU sensitivity in 
our study. In the xenograft series, DPYD expression was observed to be higher among 
non-responders. This is in concordance with the findings by Yoshinare et al. that high 
DPYD expression is associated with low 5FU sensitivity (Yoshinare et al., 2003). 
However, this trend was not observed in the primary tumors. This could be possibly due 
to the under representation of the non responders in this series.  
 
 In summary, this is the first study which identified CTPS2 as a pharmacologically 
relevant marker which could be predictive for 5FU response, through a convergence of 
pathway-based, baseline and temporal, and in-vitro siRNA investigations. Future 
investigation of CTPS2 protein levels and activity will help further elucidate the potential 






The antimetabolite, 5-fluorouracil (5FU) is the mainstay for the treatment of many cancer 
types. Inter-patient response to 5FU is however extremely variable, making it desirable to 
identify factors that influence 5FU sensitivity. Here, we describe the identification of 
cytidine triphosphate synthase II (CTPS2) as a significant determinant of 5FU sensitivity 
through an exhaustive search, involving real-time PCR analysis of 92 genes involved in 
5FU and folate transport, metabolism and downstream effects in three cancer models 
(cell lines, xenografts and primary tumors), with examination of both baseline and 
temporal data, and siRNA functional assessment. The identification of CTPS2 presents a 
potentially sensitive factor that could be used in the clinic for predicting response to 5FU, 
or devising strategies to potentiate drug activity. In addition, the pathway-based, multi-
model data integration, and multi-timepoint temporal analysis approaches used in this 
study presents useful alternative strategies to discovering determinants of drug 
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